(Hong Kong, 21April 2020) TOT BIOPHARM International Company Limited (“TOT BIOPHARM” or the “Company”; stock code: 1875.HK) is pleased to announce that the randomized Phase III clinical trial of TAB008 (Pusintin^®) has recently reached the predefined primary endpoint. The Company will continue to push forward the new drug application (NDA) of TAB008 (Pusintin^®) as scheduled.

Ms. Yeh Huang, Chun Ying, General Manager of TOT BIOPHARM, said, “We are very excited about the Phase III Clinical Trial of TAB008 (Pusintin^®) reaching the predefined primary endpoint. There are many combination therapies and other opportunities for expansion of indications which can be explored by TAB008 (Pusintin^®) in the future, which could fulfill the needs of an enormous number of patients. After the commercialization of TAB008 (Pusintin^®), it is expected to create more profits for us. In the future, we will continue to develop new anti-tumor drug products with high technological barriers and economic value, providing an appropriate and affordable product portfolio.”

About TAB008 (Pusintin^®)

TAB008 is an anti-vascular endothelial growth factor monoclonal antibody (anti-VEGF mAb), a biosimilar drug candidate for bevacizumab. Bevacizumab was approved for launch by the U.S. Food and Drug Administration as early as 2004, under the product name of Avastin^®. It has obtained recognition for treatment of seven indications, including metastatic colorectal cancer, NSCLC, malignant glioma, renal cell carcinoma, ovarian carcinoma, breast cancer and cervical cancer. According to a report by Frost & Sullivan, China’s market size for bevacizumab biosimilars will reach approximately RMB14.2 billion in 2024 through enormous market demand.